Induction of iodide uptake in transformed thyrocytes: A compound screening in cell lines

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 5, 2009, Pages 780-790

  Fröhlich, Eleonore ^a   Brossart, Peter ^a   Wahl, Richard ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Department IV Internal Medicine   (Germany)

Author keywords

Arsenic trioxide; Bortezomib; Differentiation therapy; Glitazones; HDAC inhibitors; Mevinolin; Retinoids; Sirolimus; Thyroid carcinoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; AZACITIDINE; BORTEZOMIB; CHOLESTIN; IODINE 125; MEVINOLIN; PENDRIN; RAPAMYCIN; RETINOIC ACID; RETINOL; ROSIGLITAZONE; SODIUM IODIDE SYMPORTER; THYMIDINE; THYROTROPIN; THYROTROPIN RECEPTOR; VALPROATE SEMISODIUM; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG UPTAKE; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; PROTEIN EXPRESSION; THYROID CELL; THYROID FOLLICULAR CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BORONIC ACIDS; CARCINOMA; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IODIDES; LOVASTATIN; NEOPLASM METASTASIS; OXIDES; PYRAZINES; SIROLIMUS; THYMUS GLAND; THYROID NEOPLASMS; TRETINOIN;

EID: 64649094831     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-1024-6     Document Type: Article

References (57)

1. L Davies HG Welch 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002 JAMA 295 2164 2167
2. A Lubina O Cohen M Barchana I Liphshiz I Vered S Sadetzki A Karasik 2006 Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase Thyroid 16 1033 1040
3. E Kebebew M Peng E Reiff P Treseler KA Woeber OH Clark 2006 A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer Surgery 140 960 966
4. YY Liu MP Stokkel AM Pereira EP Corssmit HA Morreau JA Romijn 2006 Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma Eur J Endocrinol 154 525 531
5. Y Zhang S Jia Y Liu B Li Z Wang H Lu 2007 A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer Nucl Med Commun 28 251 255
6. S Tepmongkol S Keelawat S Honsawek P Ruangvejvorachai 2008 Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma Thyroid 18 697 704
7. M Catalano N Fortunati M Pugliese L Costantino R Poli O Bosco 2005 Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells J Clin Endocrinol Metab 90 1383 1289
8. N Fortunati M Catalano K Arena E Brignardello A Piovesan G Boccuzzi 2004 Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells J Clin Endocrinol Metab 89 1006 1009
9. F Furuya H Shimura H Suzuki K Taki K Ohta K Haraguchi 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin Endocrinology 145 2865 2875
10. A Aparicio J Weber 2002 Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors Curr Opin Investig Drugs 3 627 623
11. MJ Provenzano MP Fitzgerald K Krager FE Domann 2007 Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC) Otolaryngol Head Neck Surg 137 722 728
12. EY Park ET Wilder MA Lane 2007 Retinol inhibits the invasion of retinoic acid-resistant colon cancer cells in vitro and decreases matrix metalloproteinase mRNA, protein, and activity levels Nutr Cancer 57 66 77
13. JJ Knox LL Siu E Chen J Dimitroulakos S Kamel-Reid MJ Moore 2005 A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix Eur J Cancer 41 523 530
14. CS Mitsiades D McMillin V Kotoula V Poulaki C McMullan J Negri 2006 Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro J Clin Endocrinol Metab 91 4013 4021
15. D Cho S Signoretti M Regan JW Mier MB Atkins 2007 The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer Clin Cancer Res 13 758s 763s
16. Z Ai W Lu S Ton H Liu T Sou Z Shen 2007 Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of cyclin D1 transcription mediated by Sp1 transcription factor Biochem Biophys Res Commun 360 684 689
17. G Baj A Arnulfo S Deaglio R Mallone A Vigone MG De Cesaris 2002 Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects Breast Cancer Res Treat 3 61 73
18. E Fröhlich B Czarnocka P Brossart R Wahl 2008 Antitumor effects of arsenic trioxide in transformed human thyroid cells Thyroid 18 1183 1193
19. T Kondo S Ezzat SL Asa 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia Nat Rev Cancer 6 292 306
20. G Salvatore F Carlomagno M Santoro 2008 Pros and cons of cellular studies in developing new drugs for thyroid cancers Thyroid 18 819 822
21. MF Herrera ID Hay PS Wu JR Goellner JJ Ryan JR Ebersold 1992 Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior World J Surg 16 669 674
22. DrugLib.com. Avandia (rosiglitazone maleate) - clinical pharmacology. http://www.druglib.com/druginfo/avandia/pharmacology/. Accessed 10 Dec 2008
23. A Thibault D Samid AC Tompkins WD Figg MR Cooper RJ Hohl 1996 Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clin Cancer Res 2 483 491
24. Blomhoff R, Beckman-Sundh U, Brot C, Solvoll K, Steingrimdóttir L, Carlsen MH. Health risks related to high intake of preformed retinol (vitamin A) in the Nordic countries. TemaNord 2003:502. ISBN: 92-893-0860-5. www.blomhoff.no/pdf%20filer/Vitamin%20A%20toxicity.pdf. Accessed 11 Dec 2008.
25. S Coelho M Vaisman D Carvalho 2005 Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer Curr Pharm Des 11 2525 2531
26. S Coelho R Corbo A Buescu D Carvalho M Vaisman 2004 Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma J Endocrinol Invest 27 334 339
27. D Simon C Korber M Krausch J Segering P Groth R Gorges 2002 Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study Eur J Nucl Med Mol Imaging 29 775 782
28. M Kitazono R Robey Z Zhan N Sarlis M Skarulis T Aikou 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells J Clin Endocrinol Metab 86 3430 3435
29. K Ohta T Endo K Haraguchi J Hershman T Onaya 2001 Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells J Clin Endocrinol Metab 86 2170 2177
30. AJ van Herle ML Agatep DN Padua III TL Totanes DV Canlapan HML van Herle 1990 Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro J Clin Endocrinol Metab 71 755 763
31. WC van Staveren DW Solis L Delys L Duprez G Andry B Franc 2007 Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype Cancer Res 67 8113 8120
32. J Xu F Moatamed JS Caldwell JR Walker Z Kraiem K Taki 2003 Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells J Clin Endocrinol Metab 88 4990 4996
33. K von Wangenheim H Peterson 1998 Control of cell proliferation by progress in differentiation: clues to mechanisms of aging, cancer causation and therapy J Theor Biol 193 663 678
34. O Bruserud BT Gjertsen T Huang 2000 Induction of differentiation and apoptosis - a possible strategy in the treatment of adult acute myelogenous leukemia Oncologist 5 454 462
35. E Frohlich F Macchicao R Wahl 2005 Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture Endocr Relat Cancer 12 1 13
36. C Schmutzler 2001 Regulation of the sodium/iodide symporter by retinoids - a review Exp Clin Endocrinol Diabetes 109 41 44
37. MP Gillam AR Sidhaye EJ Lee J Rutishauser CW Stephan P Kopp 2004 Functional characterization of pendrin in a polarized cell system. Evidence for pendrin-mediated apical iodide efflux J Biol Chem 279 13004 13010
38. JA Rillema MA Hill 2003 Pendrin transporter carries out iodide uptake into MCF-7 human mammary cancer cells Exp Biol Med (Maywood) 228 1078 1082
39. Rousset B. How iodide reaches its site of utilisation in the thyroid gland - involvement of solute carrier 26A4 (pendrin) and solute carrier 5A8 (apical iodide transporter). In: Hughes T, Dunn C, McCulloch A, editors. European Endocrine Disease 2007. London: Touch Briefings; 2007. p. 81-3.
40. G Brabant C Maenhaut J Kohrle G Scheumann H Dralle C Hoang-Vu 1991 Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation Mol Cell Endocrinol 82 R7 R12
41. T Kogai K Taki GA Brent 2006 Enhancement of sodium/iodide symporter expression in thyroid and breast cancer Endocr Relat Cancer 13 797 826
42. T Hoelting S Tezelman AE Siperstein QY Duh OH Clark 1995 Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro Thyroid 5 35 40
43. A Zielke S Hoffmann U Plaul QY Duh OH Clark M Rothmund 1999 Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion Exp Clin Endocrinol Diabetes 107 361 369
44. MJ Demeure KM Doffek SD Wilson 1997 Defective thyrotropin receptor G-protein cyclic adenosine monophosphate signaling mechanism in the FTC human follicular thyroid cancer cell line Surgery 122 1195 1201
45. H Kimura S Yamashita H Namba T Usa K Fujiyama M Tsuruta 1992 Impairment of the TSH signal transduction system in human thyroid carcinoma cells Exp Cell Res 203 402 406
46. E Kebebew MG Wong AE Siperstein QY Duh OH Clark 1999 Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function J Clin Endocrinol Metab 84 2840 2847
47. AM Meireles A Preto AS Rocha AP Rebocho V Maximo I Pereira-Castro 2007 Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines Thyroid 17 707 715
48. C Schmutzler C Hoang-Vu B Ruger J Kohrle 2004 Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses Eur J Endocrinol 150 547 556
49. I Clinckspoor L Verlinden M Verstuyf R Bouillon B Decallonne 2007 Effects of 1,25(OH)2D3 and analog WY1112 on proliferation and differentiation of FRO cells Horm Res 68 Suppl 3 32
50. C Spitzweg AE Heufelder 1998 The sodium iodide symporter: its emerging relevance to clinical thyroidology Eur J Endocrinol 138 374 375
51. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2008; Oct.14 [Epub ahead of print].
52. Laboratory Corporation of America. Valproic acid (Depakote®), serum. Laboratory Corporation of America; 2007. http://www.labcorp.com/datasets/ labcorp/html/chapter/mono/td024600.htm. Accessed 11 Dec 2008.
53. K Appleton HJ Mackay I Judson JA Plumb C McCormick G Strathdee 2007 Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors J Clin Oncol 25 4603 4609
54. RxMed. VESANOID. Herndon, VA: RxMed. http://www.rxmed.com/b.main/b2. pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs- %20V)/VESANOID.html. Accesses 11 Dec 2008.
55. TM Horton D Pati SE Plon PA Thompson LR Bomgaars PC Adamson 2007 A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study Clin Cancer Res 13 1516 1522
56. H Tedesco Silva Jr CR Felipe PG Machado R Garcia S Motegi BH Hosaka 2003 Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty Transplant Proc 35 177S 180S
57. ZX Shen GQ Chen JH Ni XS Li SM Xiong QY Qiu 1997 Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 89 3354 3360